Compare KNDI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNDI | TENX |
|---|---|---|
| Founded | 2002 | 1967 |
| Country | China | United States |
| Employees | N/A | 16 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 71.1M |
| IPO Year | 2021 | 2001 |
| Metric | KNDI | TENX |
|---|---|---|
| Price | $0.56 | $1.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 73.6K | ★ 4.5M |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.48 | $1.31 |
| 52 Week High | $1.35 | $19.40 |
| Indicator | KNDI | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 36.42 | 28.05 |
| Support Level | N/A | $1.31 |
| Resistance Level | $0.70 | $2.22 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | -0.00 | 0.36 |
| Stochastic Oscillator | 47.51 | 26.93 |
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.